Acorda Therapeutics | Evaluate

October 14, 2021

A remyelinating agent remains a distant hope

But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.

January 02, 2019

Pharma news over the Christmas period

If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.

September 11, 2018

No margin left for error at Acorda

Generic versions of Acorda’s Ampyra are about to flood the market, meaning that the company desperately needs a timely approval in October for its next big hope.

November 24, 2017

Snippet roundup: a trial miss for Bayer and Acorda cuts its losses

November 15, 2017

Sepsis signal could derail tozadenant – and perhaps even Acorda

October 04, 2017

Therapy focus – No safe haven for bio in spinocerebellar ataxia

September 01, 2017

Snippet roundup: The regulatory news is good for Lilly and Abbott, but bad for Acorda

May 25, 2017

Ocrevus survives first brush with brain infection

April 03, 2017

Patent rulings knock Acorda and Forward

April 03, 2017

Patent rulings knock Acorda and Forward

Acorda and Forward have been bashed by unfavourable US patent verdicts in multiple sclerosis, while Steadymed got a boost.

March 10, 2017

Snippet roundup: Acorda wins, Ionis loses – maybe

Load More